Q1 2025 OraSure Technologies Inc Earnings Call Transcript
Key Points
- OraSure Technologies Inc (OSUR) reported Q1 revenue in the top half of their guidance range for both total and core revenue.
- The integration of Sherlock Biosciences is progressing well, enhancing OSUR's product pipeline with molecular diagnostics innovation.
- The company is ahead of schedule in transitioning the manufacturing of SMS products to their facilities in Bethlehem, Pennsylvania.
- OSUR's international diagnostics business showed growth, driven by the hepatitis C self-test and strong international demand.
- The company has a strong balance sheet with $248 million in cash and no debt, allowing for strategic investments and stock repurchases.
- Core revenue decreased by 2% year-over-year, with Sample Management Solutions revenue declining by 16% due to disruptions in consumer genomics.
- The US diagnostics business faces headwinds due to potential budget cuts and staffing reductions in public health organizations.
- The Together Take Me Home program is expected to end due to funding cuts, impacting revenue by approximately $4 million in 2025.
- There is significant disruption from a large customer in the consumer genomics segment, with no expected revenue from them in Q2.
- Uncertainty in NIH funding is affecting academic and research labs, contributing to mixed market trends in Sample Management Solutions.
Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2025 first-quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jason Plagman, Vice President of Investor Relations. Please go ahead.
Good afternoon, and welcome to OraSure Technologies first-quarter 2025 earnings call. Participating in the call today for OTI are Carrie Eglinton Manner, our President and Chief Executive Officer; and Ken McGrath, our Chief Financial Officer. As a reminder, today's webcast is being recorded, and the recording can be found on our Investor Relations website.
Before we begin, you should know that this call may contain certain forward-looking statements, including statements with respect to revenues, expenses, profitability, earnings or loss per share and other financial performance, product development, shipments and markets,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
